MedWatch

Pharma & biotech

Sydbank: Expanded ALK approval is good news

It is good news that the FDA has approved ALK's ragweed allergy tablet for use in children – though it won't cause a huge increase in short term sales, says Sydbank senior analyst Søren Løntoft Hansen.

ALK gains important approval on difficult US market

Allergy company ALK has received the green light from the FDA to expand the use of its ragweed allergy tablet to include children. The approval is "significant" on the US market, where ALK has yet to make its big breakthrough.

Astrazeneca on vaccine skepticism: "Many forget it's a non-profit project"

The fact that many countries around the world are pausing the vaccine from Astrazeneca has no financial consequences for the pharmaceutical giant, according to the country director of Denmark and Norway. However, he does not rule out that the vaccine might suddenly be turned into a lucrative business.

Pension fund criticizes Genmab salary packages

The statutory pension fund ATP, which holds a portion of Genmab's shares, is particularly critical of the variable part of Genmab's salary packages for the executive team and board of directors. However the proposed changes to the salaries were accepted without further issue.

Analyst: Genmab share price may double

In an analysis, Jyske Bank estimates that Genmab's stock price does not reflect the potential of the company's pipeline, although it highlights one large risk within this share.

Zealand Pharma will soon launch first drug

Analyst estimates that Zealand Pharma's recently approved rescue pen Zegalogue can generate billion-kroner income for the Danish biotech company, which is getting ready to take the treatment to market.

Latest news

See all jobs